Index -
P/E 2169.02
EPS (ttm) 0.07
Insider Own 6.16%
Shs Outstand 93.73M
Perf Week -0.94%
Market Cap 13.63B
Forward P/E 11.64
EPS next Y 12.39
Insider Trans -1.33%
Shs Float 88.70M
Perf Month -8.07%
Income 16.90M
PEG -
EPS next Q -0.13
Inst Own 87.42%
Short Float 8.27%
Perf Quarter 13.23%
Sales 1.40B
P/S 9.72
EPS this Y 171.64%
Inst Trans 6.35%
Short Ratio 3.88
Perf Half Y 20.18%
Book/sh 10.17
P/B 14.18
EPS next Y 198.23%
ROA 0.54%
Short Interest 7.33M
Perf Year 38.52%
Cash/sh 14.71
P/C 9.80
EPS next 5Y -
ROE 2.02%
52W Range 55.25 - 173.25
Perf YTD 49.58%
Dividend Est. -
P/FCF -
EPS past 5Y -1.21%
ROI 0.76%
52W High -16.74%
Beta 0.89
Dividend TTM -
Quick Ratio 3.44
Sales past 5Y 32.89%
Gross Margin 85.20%
52W Low 161.07%
ATR (14) 4.85
Dividend Ex-Date -
Current Ratio 4.05
EPS Y/Y TTM 101.12%
Oper. Margin -6.76%
RSI (14) 48.23
Volatility 2.49% 2.70%
Employees 1314
Debt/Eq 1.44
Sales Y/Y TTM 43.83%
Profit Margin 1.20%
Recom 1.43
Target Price 197.20
Option/Short Yes / Yes
LT Debt/Eq 1.33
EPS Q/Q 106.22%
Payout -
Rel Volume 0.51
Prev Close 147.56
Sales Surprise 8.94%
EPS Surprise 2768.22%
Sales Q/Q 63.10%
Earnings May 01 AMC
Avg Volume 1.89M
Price 144.24
SMA20 -4.24%
SMA50 4.85%
SMA200 21.71%
Trades
Volume 964,423
Change -2.25%
Date
Action
Analyst
Rating Change
Price Target Change
Jun-26-24 Downgrade
Citigroup
Buy → Neutral
$172 → $176
May-31-24 Initiated
Piper Sandler
Overweight
$157
May-28-24 Downgrade
RBC Capital Mkts
Outperform → Sector Perform
$157 → $142
May-14-24 Upgrade
Oppenheimer
Perform → Outperform
$180
Jan-31-24 Initiated
BMO Capital Markets
Outperform
$170
Dec-13-23 Resumed
Citigroup
Buy
$113
Dec-12-23 Initiated
Deutsche Bank
Buy
$109
Nov-21-23 Initiated
Wedbush
Outperform
$224
Oct-31-23 Downgrade
Oppenheimer
Outperform → Perform
Oct-31-23 Downgrade
Cantor Fitzgerald
Overweight → Neutral
$166 → $40
Jun-23-23 Downgrade
Evercore ISI
Outperform → In-line
$139
Apr-26-23 Initiated
SMBC Nikko
Outperform
$185
Apr-04-23 Initiated
Citigroup
Buy
$179
Mar-01-23 Upgrade
Morgan Stanley
Equal-Weight → Overweight
$141 → $187
Dec-22-22 Reiterated
BTIG Research
Buy
$125 → $160
Dec-16-22 Upgrade
UBS
Neutral → Buy
$100 → $158
Apr-04-22 Resumed
Cantor Fitzgerald
Overweight
$140
Jan-05-22 Reiterated
Needham
Buy
$157 → $150
Dec-09-21 Upgrade
Oppenheimer
Perform → Outperform
$125
Nov-05-21 Upgrade
JP Morgan
Neutral → Overweight
$130
Show Previous Ratings
Jul-21-24 06:59AM
Jul-19-24 09:55AM
Jul-17-24 08:00AM
Jul-16-24 12:00PM
Jul-08-24 12:04PM
08:00AM
Loading…
Jul-06-24 08:00AM
Jul-04-24 06:35AM
Jul-03-24 10:05AM
Jun-28-24 06:30PM
Jun-26-24 10:06AM
03:45AM
Jun-24-24 02:55PM
(Investor's Business Daily)
03:49AM
Jun-21-24 05:25PM
(Yahoo Finance Video) +30.14%
05:05PM
04:28PM
Loading…
04:28PM
(Investor's Business Daily)
04:23PM
02:39PM
01:53PM
(The Wall Street Journal)
01:00PM
12:58PM
12:48PM
12:29PM
(Investor's Business Daily)
12:14PM
(The Wall Street Journal)
11:24AM
11:09AM
11:00AM
(The Wall Street Journal)
10:42AM
09:32AM
09:31AM
09:14AM
Loading…
09:14AM
08:42AM
07:52AM
07:34AM
06:40AM
(Investor's Business Daily)
Jun-20-24 05:02PM
02:13PM
01:22PM
Jun-13-24 04:04PM
(Investor's Business Daily)
01:07PM
07:00AM
Jun-06-24 07:00AM
May-31-24 05:45PM
11:31AM
May-29-24 05:48PM
08:28AM
May-28-24 10:52PM
May-24-24 11:57AM
May-23-24 07:10AM
May-17-24 08:05AM
May-14-24 07:30AM
May-04-24 12:00PM
May-03-24 10:07AM
May-02-24 03:42PM
11:30AM
11:13AM
11:08AM
07:52AM
06:01AM
(Thomson Reuters StreetEvents)
03:32AM
May-01-24 08:55PM
07:30PM
07:30PM
05:20PM
05:06PM
04:19PM
(Associated Press Finance)
04:05PM
09:15AM
Apr-30-24 06:38PM
09:28AM
Apr-29-24 03:20PM
(Investor's Business Daily)
Apr-24-24 08:30AM
Apr-13-24 09:39PM
Apr-08-24 04:13PM
(Investor's Business Daily)
Apr-06-24 08:45AM
Apr-02-24 07:04AM
Mar-29-24 04:00PM
11:30AM
Mar-26-24 07:49AM
Mar-25-24 10:00AM
Mar-17-24 08:50AM
Mar-14-24 03:53PM
Mar-13-24 08:00AM
Mar-12-24 01:18AM
Mar-11-24 09:03AM
Mar-06-24 11:54PM
Mar-04-24 09:47AM
08:30AM
Mar-02-24 12:05AM
Feb-29-24 06:16PM
12:35PM
10:52AM
09:00AM
12:00AM
Feb-28-24 06:00PM
04:23PM
(Associated Press Finance)
04:05PM
07:15AM
Feb-27-24 08:48AM
Feb-21-24 11:24AM
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
BEHRENS M KATHLEEN Director Jul 03 '24 Option Exercise 13.90 15,000 208,500 191,839 Jul 08 08:00 PM Brown Ryan Edward EVP, General Counsel Jun 25 '24 Option Exercise 62.77 23,500 1,475,095 56,086 Jun 25 08:00 PM Brown Ryan Edward EVP, General Counsel Jun 25 '24 Sale 161.61 38,957 6,296,029 17,129 Jun 25 08:00 PM Arif Bilal Chief Tech Ops Officer Jun 25 '24 Sale 163.23 3,898 636,271 17,363 Jun 25 08:00 PM Arif Bilal Chief Tech Ops Officer Jun 24 '24 Sale 163.08 7,859 1,281,621 21,261 Jun 25 08:00 PM Murray Dallan Chief Customer Officer May 02 '24 Sale 140.00 3,635 508,900 18,125 May 06 08:09 PM Boor Kathryn Jean Director Mar 11 '24 Sale 122.93 761 93,550 7,516 Mar 11 08:00 PM Wigzell Hans Lennart Rudolf Director Mar 08 '24 Option Exercise 13.90 15,000 208,500 37,840 Mar 11 08:02 PM Wigzell Hans Lennart Rudolf Director Mar 08 '24 Sale 123.25 15,000 1,848,795 22,840 Mar 11 08:02 PM Mayo Stephen Director Mar 05 '24 Sale 122.96 3,135 385,480 6,621 Mar 06 08:00 PM Arif Bilal Chief Tech Ops Officer Mar 01 '24 Sale 128.84 2,000 257,676 26,836 Mar 05 08:00 PM Brown Ryan Edward EVP, General Counsel Mar 01 '24 Sale 125.34 2,000 250,680 31,827 Mar 05 08:00 PM Estepan Ian Michael Chief Financial Officer Mar 01 '24 Sale 128.30 1,200 153,960 39,114 Mar 05 08:00 PM BEHRENS M KATHLEEN Director Nov 03 '23 Option Exercise 29.03 15,000 435,450 174,993 Nov 06 08:00 AM Barry Richard Director Nov 03 '23 Buy 78.81 50,000 3,940,500 140,000 Nov 06 08:00 AM INGRAM DOUGLAS S President & CEO Nov 03 '23 Buy 79.36 25,225 2,001,800 390,307 Nov 06 08:00 AM Chambers Michael Andrew Director Aug 14 '23 Buy 109.47 9,979 1,092,429 246,996 Aug 15 08:00 AM Chambers Michael Andrew Director Aug 11 '23 Buy 108.05 23,686 2,559,272 237,017 Aug 14 08:00 AM Chambers Michael Andrew Director Aug 10 '23 Buy 106.15 34,867 3,701,067 213,331 Aug 11 07:40 AM Wigzell Hans Lennart Rudolf Director Aug 04 '23 Option Exercise 29.03 15,000 435,450 35,994 Aug 08 08:00 PM Wigzell Hans Lennart Rudolf Director Aug 04 '23 Sale 106.72 15,000 1,600,800 20,994 Aug 08 08:00 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite